Home › Syros Pharmaceuticals Announces FDA Acceptance Of IND To Advance SY-1425 Into Phase 2 Clinical Trial
 

Keywords :   


Syros Pharmaceuticals Announces FDA Acceptance Of IND To Advance SY-1425 Into Phase 2 Clinical Trial

2016-06-01 04:49:19| drugdiscoveryonline Home Page

Syros Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s Investigational New Drug (IND) application to advance its lead drug candidate, SY-1425, a potent and selective retinoic acid receptor alpha (RARα) agonist, into a Phase 2 clinical trial in genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia (AML) and relapsed high-risk myelodysplastic syndrome (MDS) identified through its platform

Tags: trial advance phase acceptance

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
13.05Young face paying mortgage into retirement years
13.05Universal Credit claimants must seek 18 hours work
12.05Weekly Recap: Huggies Launches Skin Essentials Diaper, P&G Recognizes Key Suppliers & More
12.05California Bill Limits Skincare Sales to Teens & Persil Rebrands
12.05Kline Analysts Detail the Medical Dispensing Skin Care Market
12.05Glo30 Starts 2024 Strong with 60% Growth
12.05Zevo On-Body Repellent Teams with American Hiking Society To Provide Bug Bite Defense
12.05L\'Oréals Brand Value Soars to $13.4 Billion
More »